BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Hits New 52-Week Low – Here’s Why

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT)’s stock price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $7.60 and last traded at $7.74, with a volume of 48091 shares. The stock had previously closed at $8.13.

Analyst Ratings Changes

BBOT has been the topic of several research analyst reports. Stifel Nicolaus initiated coverage on shares of BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They set a “buy” rating and a $23.00 target price on the stock. HC Wainwright raised their price objective on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Finally, Canaccord Genuity Group started coverage on shares of BridgeBio Oncology Therapeutics in a report on Monday. They set a “buy” rating and a $23.00 price objective on the stock. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

BridgeBio Oncology Therapeutics Price Performance

The firm has a market cap of $668.22 million, a PE ratio of -5.49 and a beta of 0.22. The business’s fifty day moving average price is $8.94.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($526.11) EPS for the quarter. Analysts expect that BridgeBio Oncology Therapeutics, Inc will post -2.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BridgeBio Oncology Therapeutics

Hedge funds have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC acquired a new stake in shares of BridgeBio Oncology Therapeutics during the fourth quarter valued at $63,000. Persistent Asset Partners Ltd acquired a new position in BridgeBio Oncology Therapeutics in the 4th quarter valued at about $107,000. Squarepoint Ops LLC acquired a new position in BridgeBio Oncology Therapeutics in the 4th quarter valued at about $144,000. Quadrature Capital Ltd purchased a new position in BridgeBio Oncology Therapeutics in the 4th quarter valued at about $162,000. Finally, BIT Capital GmbH purchased a new position in BridgeBio Oncology Therapeutics in the 4th quarter valued at about $313,000. Hedge funds and other institutional investors own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.